Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Etoposide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    332 result(s) found for: Etoposide. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-003187-32 Sponsor Protocol Number: etoxel-01-2005 Start Date*: 2005-12-19
    Sponsor Name:Department of Oncology, Rigshospitalet
    Full Title: A phase II study of etoposide, oxaliplatin and capecitabine in patients with advanced hepatocellular carcinoma
    Medical condition: Advanced Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000850-48 Sponsor Protocol Number: CA184-156 Start Date*: 2012-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab plus Etoposide/Platinum versus Etoposide/Platinum in Subjects with Newly Diagnosed Extensive-Stage Disease ...
    Medical condition: Extensive Stage Disease Small Cell Lung Cancer (ED-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) IT (Completed) SE (Completed) DE (Completed) CZ (Completed) AT (Completed) GB (Completed) PT (Completed) HU (Completed) ES (Completed) NL (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-005942-41 Sponsor Protocol Number: GOIRC-05-2020 Start Date*: 2022-01-12
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC)
    Full Title: A multicenter phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell n...
    Medical condition: treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071542 Neuroendocrine carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021863-34 Sponsor Protocol Number: RHMCAN0739 Start Date*: 2011-02-10
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A phase II trial of the addition of ipilumimab to carboplatin and etoposide chemotherapy for the first line treatment of extensive small cell lung cancer
    Medical condition: Extensive stage small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002784-10 Sponsor Protocol Number: ML41599 Start Date*: 2019-10-15
    Sponsor Name:Roche Farma S.A. (Soc. Unipersonal)
    Full Title: A PHASE IIIb, SINGLE ARM STUDY OF CARBOPLATIN OR CISPLATIN PLUS ETOPOSIDE WITH ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER
    Medical condition: First-line treatment for extensive-stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002618-40 Sponsor Protocol Number: HIT-REZ-2005 Start Date*: 2005-12-13
    Sponsor Name:Rheinische Friedrich-Wilhelms-University of Bonn, University Hospital
    Full Title: HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymoma...
    Medical condition: P-HIT-REZ 2005 study: Refractory and relapsed primitive neuroectodermal brain tumours (medulloblastomas, supratentorial PNETs) E-HIT-REZ 2005 study (Phase II Study "Oral therapy with temozolomide...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007949-13 Sponsor Protocol Number: FARM6PMFJM Start Date*: 2009-09-11
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC)
    Medical condition: Previously untreated patients with extended small cells lung cancer (SCLC).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004198-28 Sponsor Protocol Number: BAY1000394/14615 Start Date*: 2014-06-18
    Sponsor Name:Bayer AG
    Full Title: A randomized, double blind, placebo-controlled, multicenter phase II study to evaluate efficacy and safety of roniciclib in subjects with extensive-stage disease small cell lung cancer (SCLC) who a...
    Medical condition: extensive-stage disease small cell lung cancer (ED SCLC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) IT (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003347-73 Sponsor Protocol Number: UMCN-AKF 07.02 Start Date*: 2007-12-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: A pharmacokinetic evaluation of the addition of Aprepitant to the Cisplatin - Etoposide (CE) treatment of patients with metastatic lung carcinoma (ACE).
    Medical condition: Nausea and vomiting after using moderate emetogenic cytostatics such as etoposide and cisplatin for the treatment of patients with metastatic lung carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-005034-42 Sponsor Protocol Number: MK-7684A-008 Start Date*: 2022-01-31
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezoliz...
    Medical condition: Extensive-stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) LT (Trial now transitioned) IE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003696-19 Sponsor Protocol Number: E7080-G000-230 Start Date*: 2020-02-28
    Sponsor Name:Eisai Ltd
    Full Title: A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adoles...
    Medical condition: Relapsed or Refractory Osteosarcoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) BE (Completed) IE (Completed) NL (Completed) IT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-016836-11 Sponsor Protocol Number: OSI-774-205 Start Date*: 2011-04-26
    Sponsor Name:OSI Pharmaceuticals LLC
    Full Title: A Randomized, Phase 2 Study of Single-agent Erlotinib versus Oral Etoposide in Patients with Recurrent or Refractory Pediatric Ependymoma
    Medical condition: Recurrent or Refractory Paediatric Ependymoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014967 Ependymoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023691-33 Sponsor Protocol Number: MUV-MEMMAT-01 Start Date*: 2011-05-05
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Kinder- und Jugendheilkunde
    Full Title: A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma and ATRT
    Medical condition: Recurrent/progressive medulloblastoma, ependymoma and ATRT
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) SE (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001125-20 Sponsor Protocol Number: FIRM-ACT Start Date*: 2004-07-26
    Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA
    Full Title: First International Randomized trial in Metastatic Adrenocortical Cancer Treatment FIRM-ACT Etoposide, Doxorubicin, Cisplatin and Mitotane vs. Streptozotocin and Mitotane
    Medical condition: Chemotherapy in patients with locally advanced or metastatic adrenocortical cancer in adults and children
    Disease: Version SOC Term Classification Code Term Level
    6.1 10001378 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004278-41 Sponsor Protocol Number: 01081 Start Date*: 2010-04-19
    Sponsor Name:Institut Jules Bordet
    Full Title: A phase II study of doxorubicin, cyclophosphamide and vindesine with valproic acid in patients with refractory or relapsing small cell lung cancer after platinum derivatives and etoposide.
    Medical condition: This is a prospective phase II study investigating well-known chemotherapeutic (doxorubicin, cyclophosphamide, vindesine) and antiepileptic (valproate) agents, in combination, for the treatment of...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002676-18 Sponsor Protocol Number: 26-01 Start Date*: 2006-11-23
    Sponsor Name:WELEDA AG DEUTSCHLAND
    Full Title: Randomized, open-label phase 2 study on post-relapse disease-free survival (PRDFS) with the Viscum-album Extract (VA-E) Iscador P or oral Etoposide in spindle-cell bone-sarcoma patients in complete...
    Medical condition: spindle-cell bone-sarcoma patients in complete remission after surgery for second relapse.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049067 Spindle cell sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004450-28 Sponsor Protocol Number: T109/2012 Start Date*: 2013-02-18
    Sponsor Name:University of Turku [...]
    1. University of Turku
    2. Turku University Hospital
    Full Title: Effect of chemotherapy on endothelial function in patients with testicular cancer
    Medical condition: Testicular cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10043362 Testis neoplasm malignant LLT
    14.1 100000004864 10043321 Testicular germ cell cancer NOS LLT
    Population Age: Adults Gender: Male
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002845-36 Sponsor Protocol Number: PK200609 Start Date*: 2006-11-14
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Pharmacokinetics and pharmacogenetics of anticancer drugs in infants and young children
    Medical condition: Any childhood cancer.
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005377-29 Sponsor Protocol Number: CNS 2004 03 Start Date*: 2006-05-03
    Sponsor Name:Dept of Pediatrics, University Hospital of North Norway
    Full Title: SIOP-LGG 2004 Cooperative multicenter Study for Children and Adolescents with Low Grade Gliome
    Medical condition: Low Grade Glioma
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Ongoing) IE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004155-39 Sponsor Protocol Number: BAY1000394/14858 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Healthcare AG
    Full Title: Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer
    Medical condition: Subjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 23:01:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA